保管試料・データ情報

ホーム > 保管試料・データ情報

保管試料の一覧

血液 組織 尿 便 唾液 消化液
診療科 対象 検体の詳細 症例数 血清 血漿 腫瘍 正常 尿 便 唾液 膵液 胆汁
消化管外科 食道・胃・大腸がん 術前・術後の血液検体および術中組織標本 1,372 11,142 10,761 1,897 1,879 0 0 0 0 0
胃がん ニボルマブ投与前後の血液検体 12 30 30 0 0 0 0 0 0 0
便潜血陽性症例 便潜血陽性症例（大腸がん、大腸ポリープ、
大腸に異常を認めない症例を含む）の血清、尿、便、唾液		 132 405 0 0 0 124 38 112 0 0
肝胆膵外科 肝・胆道・膵がん 術前・術後の血液検体および術中組織標本 1,688 17,103 17,106 2,142 1,652 0 0 0 3 77
呼吸器外科 肺がん 術前・術後の血液検体および術中組織標本 915 7,656 484 4,037 1,642 0 0 0 0 0
胸腺腫瘍 術前・術後の血液検体および術中組織標本 67 528 14 275 106 0 19 0 0 0
呼吸器・アレルギー内科 肺がん オシメルチニブ投与前後の血液検体 86 522 526 0 0 0 0 0 0 0
肺がん ペムブロリズマブ投与前後の血液検体 24 92 92 0 0 0 0 0 0 0
肺がん ニボルマブ投与前後の血液検体 70 544 517 0 0 0 0 0 0 0
健常者 がんがないことを確認済みの血液検体 600 600 0 0 0 0 0 0 0 0

バイオバンク検体を用いた研究業績

2025年

  • Koga Y, Motegi M, Ono A, et al. Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib. Respir Investig. 2025 May;63(3):394-398. doi: 10.1016/j.resinv.2025.03.006. Epub 2025 Mar 18.
  • Ishii N, Araki K, Gantumur D, et al. Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Increases in Patients With Obstructive Jaundice through the Activation of Hepatic Stellate Cells by Bile Acids. Hepatol Res. 2025. doi:10.1002/hep. (Accepted June 2025)

2024年

  • Endo M, Yazawa S, Sano R, Yokobori T, Shirabe K, Saeki H. α1-Acid Glycoprotein with Highly Fucosylated Glycans as a Potential Diagnostic Marker for Early Detection of Hepatobiliary and Pancreatic Cancers. Diagnostics (Basel). 2024 Dec;15(1):40. doi: 10.3390/diagnostics15010040.PMID: 39795568
  • Fukushima R, Harimoto N, Okuyama T, et al. Impact of the serum creatinine and cystatin C ratio for prediction of sarcopenia and prognosis in biliary tract cancer. Int J Clin Oncol. 2024 Jul;29(7):1002-1011. doi: 10.1007/s10147-024-02539-7. Epub 2024 Apr 29.PMID: 38683456

2023年

  • Tsukagoshi M, Watanabe A, Araki K, et al. Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Ann Gastroenterol Surg. 2023;7(4):656-665. doi:10.1002/ags3.12671
  • Kubo N, Yazawa S, Yokobori T, et al. The malignant potential of pancreatic intraductal papillary mucinous neoplasm is reflected in expression levels of fucosylated glycans in α1-acid glycoprotein. J Hepatobiliary Pancreat Sci. 2023 Apr;30(4):503-513.
  • Sano R, Yokobori T, Harimoto N, et al. A novel genotyping method for rapid identification of the Le gene to select patients for diagnosis with CA19-9. Clin Chim Acta. 2023 Jan;538:181-188. doi: 10.1016/j.cca.2022.11.006. Epub 2022 Nov 17.PMID: 36403666

2022

  • Hagiwara K, Araki K, Ishii N, et al. The ratio of creatinine and cystatin C estimated glomerular filtration rates as a surrogate marker in patients with hepatocellular carcinoma undergoing hepatic resection. JHepatobiliary Pancreat Sci. 2022 Sep;29(9):964-973. doi: 10.1002/jhbp.1164. Epub 2022 May 20.

2021

  • Kuriyama K, Yokobori T, Sohda M, et al. Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab. Oncol Lett. 2021 Jan;21(1):11. doi: 10.3892/ol.2020.12272. Epub 2020 Nov 3.PMID: 33240417

2020

  • Nakazawa N, Yokobori T, Kaira K, et al. High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors. Ann Surg Oncol. 2020 Mar;27(3):933-942. doi: 10.1245/s10434-019-07878-8. Epub 2019 Sep 30.PMID: 31571056

2019

  • Yokobori T, Yazawa S, Asao T, et al. Fucosylated α1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. Sci Rep. 2019 Oct;9(1):14503. doi: 10.1038/s41598-019-51021-2.PMID: 31601857

2018

  • Yazawa S, Yokobori T, Kaira K, Kuwano H, Asao T. A new enzyme immunoassay for the determination of highly sialylated and fucosylated human α1-acid glycoprotein as a biomarker of tumorigenesis. Clin Chim Acta. 2018 Mar;478:120-128.